SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares
SOPHiA GENETICS (Nasdaq: SOPH) said it closed an underwritten public offering after oversubscribed demand. The company sold 12,104,900 ordinary shares at $4.75 each, and underwriters fully exercised their option to buy an additional 1,578,900 shares. Gross proceeds were $57.5 million. TD Cowen led; Guggenheim, BTIG and Craig-Hallum also managed.
How this was made
The 30-second read
Why it matters
Closing details (gross proceeds, share count, and option exercise) confirm the financing is completed at a fixed public price, creating an identifiable dilution/overhang profile for SOPH.
Market read
Traders can update SOPH’s near-term supply/dilution expectations based on the final share issuance and offering completion.
What to watch
The article omits the stated use of proceeds and any expected timeline for deploying capital, which can be the key driver of whether dilution is viewed as value-accretive.
Background
SOPHiA GENETICS announced and then closed an underwritten public offering under an effective Form F-3 registration statement.
Ticker impact
SOPHiA GENETICS closed a $57.5M underwritten public offering and fully exercised the underwriters’ option for 1,578,900 additional shares at $4.75.
Near-term downside risk from dilution/overhang, partially offset by strong investor demand for the deal.
The article provides concrete deal size, pricing ($4.75), and share quantities, but no stated use of proceeds or guidance impact, limiting conviction on magnitude/direction.
Market effects
Adds to the broader biotech/healthcare-tech financing backdrop where AI/precision-medicine names may access capital via equity raises.
Limited; this is a Nasdaq-listed US equity financing with no Switzerland listing impact beyond offering mechanics.
Low; the news is company-specific and does not indicate sector-wide regulatory or demand shifts.
Counterpoint
Oversubscription can signal the market is willing to fund the story despite dilution, reducing the probability of a sustained selloff.
Key entities
- companySOPHiA GENETICS
Nasdaq-listed AI-driven precision medicine company that closed a $57.5M public offering at $4.75/share.
- financial_advisorTD Cowen
Lead book-running manager for the offering.
- financial_advisorGuggenheim Securities
Book-running manager for the offering.
